Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Hims & Hers Health (HIMS – Research Report), ...

Discover how Hims & Hers Health closed 2024 with strong growth, expanding weight-loss solutions, and innovation-focused investments in ...

Walgreens Boots Alliance shares traded higher Monday following reports that multiple lenders are preparing to back a ...

Hims shares have roughly doubled since the start of the year, despite the FDA’s announcement last week that Novo Nordisk’s ...

Chegg faces challenges from Google AI, impacting traffic and revenue. Learn how Chegg plans to innovate with AI tools and ...

Andrew Dudum; Chairman of the Board, Chief Executive Officer; Hims & Hers Health Inc Oluyemi Okupe; Chief Financial Officer; Hims & Hers Health Inc Good afternoon, ladies and gentlemen, and thank you ...

Valued at a market cap of $17.7 billion, Ulta Beauty, Inc. (ULTA) is a leading beauty retailer in the United States, offering ...

US stocks sold off into the close on Monday as investors weighed the prospects of President Donald Trump's tariff policies ...